Unknown
PHASE4
INTERVENTIONAL
NCT04722640
Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
Approximately 80 patients affected by moderate to severe psoriasis will be screened for the presence of LL37( and ADAMTSL5 autoreactive T-cells in their blood at Day 0. Patients whose lymphocytes reacted with proliferation to LL37 or ADAMTSL5 will receive SKYRIZI (Risakizumab) at Day 1, week 4, 16, 28, 40. LL37 and ADAMTSL5-specific T-cell responses will be evaluated at Day 0, week 16, week 28 and week 52. Each patient will be followed for 52 weeks.
Interventions
Name:
SKYRIZI
Type:
DRUG
Description:
SKYRIZI
Primary Outcomes
Measure:
Proportion of activated autoantigen-specific T-cells
TimeFrame:
12 Months
Description:
Proportion of activated autoantigen-specific T-cells as measured by LL37 and ADAMTSL5 antigens by antigenic-specific proliferation assay at 28 weeks with respect to baseline.
Trial Information
NCT ID
NCT04722640
Status
Unknown
Study Type
INTERVENTIONAL
Phases
PHASE4
Sponsor
Istituto Clinico Humanitas
Last Updated
December 15, 2025